Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Dispatch

Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan

Chun-Hsing Liao, Yu-Tsung Huang, Chih-Cheng Lai, Cheng-Yu Chang, Fang-Yeh Chu, Meng-Shiuan Hsu, Hsin-Sui Hsu, and Po-Ren Hsueh
Author affiliations: Author affiliations: Far Eastern Memorial Hospital, Taipei, Taiwan (C.-H. Liao, C.-C. Lai, C.-Y. Chang, F.-Y. Chu, M.-S. Hsu, H.-S. Hsu); National Taiwan University College of Medicine, Taipei (Y.-T. Huang, P.-R. Hsueh)

Main Article

Table A1

Distribution and clinical characteristics of 225 patients with Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*

Characteristic K1, n = 41 K2, n = 37 Non–K1/K2, n = 147 Univariate analysis (K1 vs. non– K1/K2)
Univariate analysis (K2 vs. non–K1/K2)
OR (95% CI) p value OR (95% CI) p value
Age, y 61.8 ± 13.8 58.6 ± 15.1 62.2 ± 16.4 1.00 (0.98–1.02) 0.88 0.99 (0.96–1.01) 0.23
M:F 26:15 24:13 95:52 0.95 (0.46–1.95) 0.89 1.01 (0.58–2.15) 0.98
Source of patients
Emergency department 36 (87.8) 22 (59.5) 75 (51.0) 6.91 (2.57–18.60) <0.001 1.41 (0.68–2.93) 0.36
Ward 5 (12.2) 8 (21.6) 47 (17.0) 0.30 (0.11–0.80) 0.017 0.59 (0.25–1.38) 0.22
Intensive care unit 0 7 (18.9) 25 (32.0) NA NA 1.14 (0.45–2.88) 0.78
Severity of disease (McCabe classification)
Nonfatal 31 (75.6) 24 (64.9) 79 (53.7) 2.67 (1.22–5.84) 0.014 1.59 (0.75–3.36) 0.23
Ultimately fatal 7 (17.1) 8 (21.6) 50 (34.0) 0.40 (0.17–0.97) 0.041 0.54 (0.23–1.26) 0.15
Rapidly fatal 3 (7.3) 5 (13.5) 18 (12.3) 0.57 (0.16–2.02) 0.38 1.12 (0.39–3.24) 0.84
Pittsburgh bacteremia score 2.7 ± 3.1 5.0 ± 5.3 4.4 ± 4.7 0.90 (0.81–0.99) 0.032 1.03 (0.95–1.10) 0.50
Underlying illness, condition, or value
Diabetes mellitus 19 (46.3) 14 (37.8) 54 (36.7) 1.49 (0.74–2.99) 0.27 1.05 (0.50–2.21) 0.90
End-stage renal disease 1 (2.4) 1 (2.7) 8 (5.4) 0.43 (0.05–3.58) 0.44 0.48 (0.06–3.99) 0.50
Heart disease 4 (9.8) 8 (21.6) 33 (22.5) 0.37 (0.12–1.12) 0.08 0.95 (0.40–2.28) 0.91
Stroke 4 (9.8) 3 (8.1) 21 (14.3) 0.65 (0.21–2.01) 0.45 0.53 (0.15–1.88) 0.33
Active malignancy 5 (12.2) 6 (16.2) 29 (19.7) 0.57 (0.20–1.57) 0.27 0.79 (0.30–2.07) 0.63
Liver cirrhosis 4 (9.8) 6 (16.2) 23 (15.7) 0.58 (0.19–1.79) 0.35 1.04 (0.39–2.78) 0.93
Surgery within 3 mo 4 (9.8) 8 (21.6) 45 (30.6) 0.25 (0.08–0.73) 0.011 0.63 (0.27–1.47) 0.28
CT within 3 mo 2 (4.9) 3 (8.1) 16 (10.9) 0.42 (0.09–1.91) 0.26 0.72 (0.20–2.62) 0.62
Creatinine level, mg/dL 1.7 ± 1.9 1.6 ± 1.4 1.9 ± 2.0 0.93 (0.76–1.13) 0.45 0.91 (0.73–1.14) 0.42
Albumin level, g/dL† 2.8 ± 0.6 2.7 ± 0.6 2.7 ± 0.7 1.13 (0.57–2.23) 0.74 0.85 (0.43–1.71) 0.65
Type of infection
Primary bacteremia 11 (26.8) 12 (32.4) 39 (26.5) 1.02 (0.47–2.22) 0.97 1.33 (0.61–2.90) 0.47
Respiratory tract 4 (9.8) 6 (16.2) 30 (20.4) 0.42 (0.14–1.28) 0.13 0.76 (0.29–1.98) 0.57
Urinary tract 2 (4.9) 3 (8.1) 30 (20.4) 0.20 (0.05–0.88) 0.033 0.34 (0.10–1.20) 0.09
Biliary tract 3 (7.3) 3 (8.1) 26 (17.7) 0.37 (0.11–1.28) 0.12 0.41 (0.12–1.44) 0.16
Liver abscess 19 (46.3) 5 (13.5) 6 (4.1) 20.3 (7.31–56.40) <0.001 3.67 (1.06–12.8) 0.041
Intraabdominal 1 (2.4) 5 (13.5) 8 (5.4) 0.43 (0.05–3.58) 0.44 2.72 (0.83–8.85) 0.10
Catheter related 0 0 6 (4.1) NA NA NA NA
Soft tissue 0 1 (2.7) 2 (1.36) NA NA 2.01 (0.18–22.83) 0.57
Meningitis 1 (2.4) 2 (5.4) 0 NA NA NA NA
TTP, h 14.4 ± 18.5 12.1 ± 12.1 13.1 ± 16.3 1.00 (0.99–1.02) 0.65 1.00 (0.97–1.02) 0.75
TTP<7 h 6 (14.6) 7 (18.9) 32 (21.8) 0.62 (0.24–1.59) 0.32 0.84 (0.34–2.09) 0.71
14-d mortality rate 4 (9.8) 10 (27.0) 35 (23.8) 0.35 (0.12–1.04) 0.058 1.19 (0.52–2.69) 0.68
In-hospital mortality rate 6 (14.6) 16 (43.2) 51 (34.7) 0.32 (0.13–0.82) 0.017 1.43 (0.70–2.99) 0.34
ESBL producer 0 0 4 (2.7) NA NA NA (NA) NA
Effective empirical agent 35 (85.4) 36 (97.3) 138 (93.9) 0.38 (0.13–1.14) 0.08 2.35 (0.29–19.14) 0.43

*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.

Main Article

TOP